As of May 31
| -0.20 / -0.59%|
The 14 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 38.50, with a high estimate of 50.00 and a low estimate of 25.00. The median estimate represents a +13.60% increase from the last price of 33.89.
The current consensus among 19 polled investment analysts is to Buy stock in Myriad Genetics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.